Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name H19
   Synonyms H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2
   Region GRCh38_11:1995176-2001470    Sequence
   Ensembl ENSG00000130600
   RefSeq NR_002196
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name lung adenocarcinoma
   ICD-0-3 C34  M8140/3
   Methods qPCR, RNAi, Western blot, Flow cytometry assay etc.
   Sample LUAD tissues, cell lines (A549, A549/DDP)
   Expression Pattern up-regulated
   Function Description

In our study, the expression of H19 in cisplatin-resistant A549/DDP cells was unregulated. Knockdown of H19 restored the response of A549/DDP cells to cisplatin. H19-mediated chemosensitivity enhancement was associated with metastasis, induction of G0/G1 cell-cycle arrest, cell proliferation, and increased apoptosis. Furthermore, lncRNA H19 expression was significantly related to TNM stage and metastasis. Overexpression of H19 was negatively correlated with cisplatin-based chemotherapy response in patients.

   Pubmed ID 27911863
   Year 2017
   Title Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.
   External Links
   Links for  H19 GenBank       HGNC       lncrnadb       Noncode
   Links for  lung adenocarcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.